RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will get treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.In general, our present-day work highlights the potential utilization of ARV-825 in combin